NCT06641388
A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Chinese Healthy Male Subjects
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Not Yet Recruiting
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Area under curve (AUC)
Timeframe: Baseline till last follow-up visit( up to day 43 or day 57)
Maximum (peak) plasma concentration (Cmax)
Timeframe: Baseline till last follow-up visit( up to day 43 or day 57)
Incidence of adverse events(AE)
Timeframe: From the time of signing the informed consent form till last follow-up visit( up to day 43 or day 57)
Secondary (4)
Free protein convertase of proprotein convertase subtilisin/kexin type 9 (PCSK-9)
Immunogenicity index
PCSK-9 concentration
Serum Low-density lipoprotein Cholesterol (LDL-C) concentration
Arms and interventions
Ebronucimab 150mg (after the change)Experimental
Ebronucimab 150mg Single subcutaneous injection into the abdomen.
Ebronucimab 150mg (before the change)Experimental
Ebronucimab 150mg Single subcutaneous injection into the abdomen.
Drugs: Ebronucimab
Sites
1 site in 1 country
- The Third Xiangya Hospital of Central South UniversityChangsha, Hunan, China